抗新型冠状病毒小分子化合物研究进展  

Research Progress on Anti-SARS-CoV-2 Small-Molecule Compounds

作　　者：徐向荣 姚雷[2] XU Xiangrong;YAO Lei(Yantai University Hospital,Yantai,Shandong,China 264005;School of Pharmacy,Yantai University,Yantai,Shandong,China 264005)

机构地区：[1]烟台大学校医院,山东烟台264005 [2]烟台大学药学院,山东烟台264005

出　　处：《中国药业》2022年第3期1-8,共8页China Pharmaceuticals

摘　　要：目的总结抗严重急性呼吸综合征冠状病毒2(SARS-CoV-2)小分子化合物的研究进展。方法采用计算机检索SciFinder、PubMed、中国知网、万方、维普等数据库中相关文献,检索时限为2019年1月至2021年3月,中英文关键词为"COVID-19""SARS-CoV-2""small molecule""新型冠状病毒"。结果抗SARS-CoV-2小分子化合物主要来源于天然产物或合成化合物的虚拟筛选、先导化合物优化、人工智能从头设计,以及老药新用。结论通过对病毒结构及复制组装过程中各主要靶点的研究,利用现代新药研发技术将加速抗SARS-CoV-2小分子化合物药物的研发。Objective To summarize the research progress on anti-severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)small-molecule compounds.Methods The related literature in the database such as SciFinder,PubMed,CNKI,WanFang,VIP from January 2019 to March 2021 were retrieved with the keywords of "COVID-19" "SARS-CoV-2" "small molecule"(English) and "SARS-CoV-2"(Chinese).Results The anti-SARS-CoV-2 small-molecule compounds were mainly derived from virtual screening of natural products or synthetic compounds,optimization of lead compounds,artificial intelligence de novo design,and new use of old drugs.Conclusion Through the research on the main structure of virus and the main targets in the process of replication and assembly,the utilization of modern techniques for new drug research will accelerate the research and development of anti-SARS-CoV-2 small-molecule agent.

关 键 词：严重急性呼吸综合征冠状病毒2 小分子化合物 新型冠状病毒肺炎 

分 类 号：R978.7[医药卫生—药品]